Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleThe FOMC raised the federal funds rate 25 basis points to 3.75-4.00 percent in a unanimous 12-0 vote, the first hike since July 2023, with new projections showing 16 of 18 officials expect at least one more hike this year.
The FDA cleared Medtronic's LigaSure vessel-sealing instrument for the Hugo robotic surgery system, closing the biggest instrument gap in Hugo's US launch, though the robot's urology-only label still sets the ceiling on the near-term market.
Vera Therapeutics reported final ORIGIN 3 results showing TRUTAKNA cut the risk of a composite kidney disease progression endpoint by 76 percent in IgA nephropathy, the confirmatory data needed to convert its accelerated approval into a full one.
Summit Therapeutics presented updated HARMONi overall survival data showing a 0.76 hazard ratio at WCLC 2026, while partner Akeso's China-only HARMONi-2 trial delivered a clean survival win against pembrolizumab, with an FDA decision due November 14.
California and eleven other states have agreed to October settlement talks in their antitrust suit to block Paramount Skydance's roughly $110 billion Warner Bros. Discovery acquisition, with a $7 million daily ticking fee scheduled to start accruing on October 1.
Investors have approached OpenAI about a new private round at a $1.2 trillion pre-IPO valuation, a 41 percent step up from March, at a moment when the company's projected annual cash burn rivals the revenue behind that number.
Canada's Productivity Mega Deduction cuts the marginal effective tax rate on new business investment from 13 to 6.4 percent, the lowest in the G7, at a five-year cost of about $36 billion as Ottawa courts capital at its first investment summit.
The Senate blocked debate on the Digital Asset Market Clarity Act on a 49-50 cloture vote, with zero Democratic support and four Republican defections, sending bitcoin and crypto stocks tumbling even though the bill itself was never voted on.
The Supreme Court declined to stay an injunction against the USPS Ballot Mail rule, citing both the merits and the clock, while President Trump attacked the Court and his own administration promised compliance.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.